HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells

Oncotarget

Volumn 5, Issue 10, 2014, Pages 3333-3349

  Chen, Dong Qin ^a   Pan, Ban Zhou ^a   Huang, Jia Yuan ^a   Zhang, Kai ^a   Cui, Shi Yun ^a   De, Wei ^b   Wang, Rui ^a   Chen, Long Bang ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; E2F3; Histone deacetylase; Lung adenocarcinoma; MiR 200b

Indexed keywords

AURORA A KINASE; CASPASE 3; DOCETAXEL; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE H3; MICRORNA 200B; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; SURVIVIN; TRANSCRIPTION FACTOR E2F3; TRICHOSTATIN A; VALPROIC ACID; E2F3 PROTEIN, HUMAN; HDAC1 PROTEIN, HUMAN; HDAC4 PROTEIN, HUMAN; HISTONE DEACETYLASE; MICRORNA; MIRN200 MICRORNA, HUMAN; REPRESSOR PROTEIN;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UPREGULATION; ADENOCARCINOMA; CHROMATIN IMMUNOPRECIPITATION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; E2F3 TRANSCRIPTION FACTOR; FLOW CYTOMETRY; GENE SILENCING; HISTONE DEACETYLASE 1; HISTONE DEACETYLASES; HUMANS; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84902073116     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1948     Document Type: Article

References (48)

1. Society AC. Cancer Facts & Figures 2013. Atlanta: American Cancer Society. 2013.
2. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
3. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, and Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013; 123(6):2395-2407.
4. Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G, Wright G, Staudt LM, Zhao Y, McKeithan TW, Chan WC, and Fu K. The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia. 2012; 26(5):1064-1072.
5. Siemens H, Jackstadt R, Kaller M, and Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013; 4(9):1399-1415.
6. Ory B and Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity. Oncotarget. 2011; 2(3):259-264.
7. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, de Carvalho AC, Slavin S, Jacoby E, Yalon M, Toren A, Mikkelsen T, and Brodie C. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013; 4(5):665-676.
8. Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, and Ellisen LW. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest. 2011; 121(2):809-820.
9. Wang Q, Chen W, Bai L, Chen W, Padilla MT, Lin AS, Shi S, Wang X, and Lin Y. Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. J Biol Chem. 2014; 289(9):5654-5663.
10. Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, Fang Y, Lin X, Xu Y, Xu W, Shen H, and Wen J. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014 Feb 8. doi: 10.1002/ijc.28774. [Epub ahead of print].
11. Feng X, Wang Z, Fillmore R, and Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014; 344(2):166-173.
12. Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P, and Garcia-Foncillas J. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011; 29(11):1661-1671.
13. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, and Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010; 39(5):761-772.
14. Uhlmann S, Zhang JD, Schwager A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S, and Sahin O. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene. 2010; 29(30):4297-4306.
15. Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yang Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, et al. A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Mol Cell Biol. 2014; 34(3):533-550.
16. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P, and Kelly K. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013; 32(3):296-306.
17. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, Song E, and Li J. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012; 31(4):432-445.
18. Feng B, Wang R, Song HZ, and Chen LB. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer. 2012; 118(13):3365-3376.
19. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, and Belinsky SA. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011; 71(8):3087-3097.
20. Wee EJ, Peters K, Nair SS, Hulf T, Stein S, Wagner S, Bailey P, Lee SY, Qu WJ, Brewster B, French JD, Dobrovic A, Francis GD, Clark SJ, and Brown MA. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene. 2012; 31(38):4182-4195.
21. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, and Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009; 138(5):1019-1031.
22. Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, and Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. Hepatology. 2011; 53(1):148-159.
23. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, and Keating MJ. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood. 2012; 119(5):1162-1172.
24. Wendtner CM. Cocktail of eternity: HDAC meets miR. Blood. 2012; 119(5):1095-1096.
25. Sikandar S, Dizon D, Shen X, Li Z, Besterman J, and Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget. 2010; 1(7):596-605.
26. Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, Schulte JH, Fischer M, De Preter K, Pattyn F, Castoldi M, Muckenthaler MU, Kulozik AE, Westermann F, Witt O, and Deubzer HE. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013; 41(12):6018-6033.
27. Buurman R, Gurlevik E, Schaffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kuhnel F, and Skawran B. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology. 2012; 143(3):811-820 e811-815.
28. Yuan JH, Yang F, Chen BF, Lu Z, Huo XS, Zhou WP, Wang F, and Sun SH. The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology. 2011; 54(6):2025-2035.
29. He L, Yang H, Ma Y, Pledger WJ, Cress WD, and Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem. 2008; 283(45):31012-31020.
30. Jiang Y, Saavedra HI, Holloway MP, Leone G, and Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004; 279(39):40511-40520.
31. Druz A, Betenbaugh M, and Shiloach J. Glucose depletion activates mmu-miR-466h-5p expression through oxidative stress and inhibition of histone deacetylation. Nucleic Acids Res. 2012; 40(15):7291-7302.
32. Jayathilaka N, Han A, Gaffney KJ, Dey R, Jarusiewicz JA, Noridomi K, Philips MA, Lei X, He J, Ye J, Gao T, Petasis NA, and Chen L. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012; 40(12):5378-5388.
33. Rodriguez-Paredes M and Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011; 17(3):330-339.
34. Wang X, Yan Z, Fulciniti M, Li Y, Gkotzamanidou M, Amin SB, Shah PK, Zhang Y, Munshi NC, and Li C. Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. Leukemia. 2014; 28(4):894-903.
35. Hirose T and Horvitz HR. An Sp1 transcription factor coordinates caspase-dependent and-independent apoptotic pathways. Nature. 2013; 500(7462):354-358.
36. Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C, Minvielle S, Tai YT, Tassone P, Avet-Loiseau H, Hideshima T, Anderson KC, and Munshi NC. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011; 17(20):6500-6509.
37. Kou XX, Hao T, Meng Z, Zhou YH, and Gan YH. Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion. Carcinogenesis. 2013; 34(1):58-67.
38. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcene A, Verdin E, and Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene. 2009; 28(2):243-256.
39. Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Muller-Tidow C, Bohlander SK, Tenen DG, and Behre G. C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood. 2010; 116(25):5638-5649.
40. Lui JC and Baron J. Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3. Proc Natl Acad Sci U S A. 2013; 110(15):6181-6186.
41. Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL, Davis S, Zhu YJ, Pineda M, Meltzer PS, and Kovar H. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res. 2013; 23(11):1797-1809.
42. Shen H, Morrison CD, Zhang J, Underwood W, 3rd, Yang N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, Wang J, et al. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget. 2013; 4(11):2124-2134.
43. You JS, Kang JK, Lee EK, Lee JC, Lee SH, Jeon YJ, Koh DH, Ahn SH, Seo DW, Lee HY, Cho EJ, and Han JW. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene. 2008; 27(10):1376-1386.
44. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, and Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005; 45:495-528.
45. Wu CC, Yang TY, Yu CT, Phan L, Ivan C, Sood AK, Hsu SL, and Lee MH. p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle. 2012; 11(18):3433-3442.
46. Wang R, Huang J, Feng B, De W, and Chen L. Identification of ING4 (inhibitor of growth 4) as a modulator of docetaxel sensitivity in human lung adenocarcinoma. Mol Med. 2012; 18:874-886.
47. Wang R, Wang ZX, Yang JS, Pan X, De W, and Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011; 30(23):2644-2658.
48. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, and Goodall GJ. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008; 68(19):7846-7854.